465 related articles for article (PubMed ID: 26103029)
1. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Lian Y; Yin H; Pollak MN; Carrier S; Platt RW; Suissa S; Azoulay L
Eur Urol; 2016 Nov; 70(5):808-815. PubMed ID: 27178449
[TBL] [Abstract][Full Text] [Related]
3. Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
Deng T; Duan X; Liu B; Lan Y; Cai C; Zhang T; Zhu W; Mai Z; Wu W; Zeng G
Neoplasma; 2018; 65(2):216-221. PubMed ID: 29534582
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.
Li WQ; Qureshi AA; Robinson KC; Han J
JAMA Intern Med; 2014 Jun; 174(6):964-70. PubMed ID: 24710960
[TBL] [Abstract][Full Text] [Related]
6. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.
Matthews A; Langan SM; Douglas IJ; Smeeth L; Bhaskaran K
PLoS Med; 2016 Jun; 13(6):e1002037. PubMed ID: 27299522
[TBL] [Abstract][Full Text] [Related]
8. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.
Azzouni F; Abu samra K
J Sex Med; 2011 Oct; 8(10):2894-903. PubMed ID: 21771280
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.
Tang H; Wu W; Fu S; Zhai S; Song Y; Han J
J Am Acad Dermatol; 2017 Sep; 77(3):480-488.e9. PubMed ID: 28728871
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
11. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
12. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
[TBL] [Abstract][Full Text] [Related]
13. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
14. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Shkolyar E; Li S; Tang J; Eisenberg ML
J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
[TBL] [Abstract][Full Text] [Related]
15. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review.
Cilio S; Briatico G; Brancaccio G; Capone F; Ferro M; Imbimbo C; Salonia A; Argenziano G; Crocetto F
J Basic Clin Physiol Pharmacol; 2023 Nov; 34(6):691-697. PubMed ID: 37982667
[TBL] [Abstract][Full Text] [Related]
17. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
Chang LL; Ma M; Allmen Hv; Henderson SC; Harper K; Hornbuckle K
Curr Med Res Opin; 2010 Jun; 26(6):1451-9. PubMed ID: 20394470
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
Montorsi F; Aversa A; Moncada I; Perimenis P; Porst H; Barker C; Shane MA; Sorsaburu S
J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928
[TBL] [Abstract][Full Text] [Related]
19. Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms.
Huang W; Sundquist J; Sundquist K; Ji J
Gastroenterology; 2019 Sep; 157(3):672-681.e4. PubMed ID: 31103628
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
Kamenov ZA
J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]